---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-046436"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:13:33.858679+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oramed extends $20M stock buyback program through June 2026

## Summary
- Board extended share repurchase program by one year, now expiring June 2026.
- Maximum authorization remains $20M; $2.494M in shares repurchased to date.
- Repurchases may occur via open market or private transactions; no obligation to buy.
- Board may terminate, increase, or decrease authorization at any time.

## SEC filing metadata
- accession: 0001213900-25-046436
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025046436/0001213900-25-046436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025046436/ea0243059-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-046436
- JSON: https://secwatch.observer/filing/0001213900-25-046436.json
- Plain text: https://secwatch.observer/filing/0001213900-25-046436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.